Lumenis

Lumenis is one of the oldest and most established manufacturers of energy-based medical devices in the world. Widely recognized in aesthetic medicine as the developer of the M22 and Stellar M22 intense pulsed light (IPL) systems, the AcuPulse and UltraPulse fractional CO2 lasers, and the LightSheer diode hair removal line, the company has played a foundational role in laser and IPL engineering.

For clinic directors, dermatologists, and buyers evaluating capital equipment, the commercial history of Lumenis is complex. In 2021, the company underwent a major structural split, dividing its surgical and urology business from its aesthetic and ophthalmic business. This corporate division is not merely a footnote; it is visible across international regulatory registries and directly affects how product registrations, licenses, recalls, and adverse event profiles are tracked.

This profile provides an evidence-first, registry-driven analysis of Lumenis, compiling active registrations, recall histories, and post-market surveillance data across the United States, Europe, the United Kingdom, Canada, Australia, Brazil, South Korea, Singapore, Taiwan, Indonesia, and Israel.

---

What the Global Data Shows: Modality and Registry Footprint

An analysis of global medical device registries reveals how Lumenis's global operations are managed today under two distinct corporate groups: Lumenis Be Ltd. (handling aesthetics and ophthalmology) and Boston Scientific Corporation (which acquired and registers the surgical/urology laser line).

The table below summarizes Lumenis's active registrations and regulatory footprint across 11 major jurisdictions.

[!IMPORTANT] Regulatory Interpretation Warning: The registration counts below represent the total number of active, historical, or approved database entries registered under the Lumenis name or its local distributors. These figures reflect regulatory filings, product variations, and administrative submissions. They do not correlate with sales volume, installed base, or local market share.

---

Who Owns Lumenis Today? The Boston Scientific Split

Lumenis's corporate lineage is unusually tangled, which is part of why ownership questions are so common. The modern company was formed in 2001, when Israeli firm ESC Medical Systems (founded 1991 in Yokneam, Israel) acquired the US-based Coherent Medical business (Coherent, Inc. was founded in 1966 in California). The merged entity was renamed Lumenis Ltd. in September 2001 and has remained headquartered in Yokneam.

• The 2021 Acquisition Split: On March 3, 2021, Boston Scientific Corporation announced a definitive agreement to acquire the global surgical and urology business of Lumenis Ltd. from Baring Private Equity Asia (BPEA) for $1.07 billion in upfront cash.
• What Boston Scientific Acquired: Boston Scientific took ownership of Lumenis's urology and specialty surgery laser systems, fibers, and accessories. This included the flagship Lumenis Pulse 120H and Pulse 60H holmium laser systems, the VersaPulse Powersuite, the VersaCut tissue morcellator, and surgical fibers.
• What BPEA (now EQT) Retained: Baring Private Equity Asia retained ownership of the Lumenis aesthetics and ophthalmology businesses. To manage this retained business, the corporate entity was restructured as Lumenis Be Ltd.
• Headquarters: Both Lumenis Be Ltd. and the legacy surgical manufacturing operations remain based in the technology park in Yokneam, Israel, though they operate under separate corporate management.

---

Registry Evidence of the Corporate Split

The 2021 split is not just an internal corporate arrangement; it is clearly documented in national registries where the two corporate groups operate side-by-side but register different device portfolios.

[Lumenis Registry Separation Scheme]
  
                             LUMENIS BRAND RECORD
                                      |
         +----------------------------+----------------------------+
         |                                                         |
  LUMENIS BE LTD. (Aesthetics / Eye)            BOSTON SCIENTIFIC (Surgical / Urology)
  - Registrant: ARQON / Brazil Import           - Registrant: Boston Scientific Asia Pac / BR
  - Representative Devices:                     - Representative Devices:
    * Stellar M22 IPL System                      * Lumenis Pulse 120H Holmium Laser
    * LightSheer Diode Laser                      * Lumenis Pulse 60H Holmium Laser
    * Selecta Duet Ophthalmic                     * VersaPulse Powersuite
    * Splendor-X Alexandrite/Nd:YAG               * VersaCut Tissue Morcellator

Singapore (HSA)

In the Singapore Health Sciences Authority (HSA) registry, Lumenis devices are split between two distinct registrants:

1. ARQON Pte. Ltd. (Regulatory Consultant & Importer): Registers the aesthetic and ophthalmic portfolio of Lumenis Be Ltd., including the Stellar M22 aesthetic treatment system, the M22 skin surface treatment system, and the Selecta Duet ophthalmic laser system.
2. Boston Scientific Asia Pacific Pte. Ltd.: Registers the urology and surgical laser portfolio, including the Lumenis Pulse 60H, Lumenis Pulse Systems, VersaCut, and VersaPulse Powersuite.

Brazil (ANVISA)

The Brazilian Health Regulatory Agency (ANVISA) registry shows a similar division across its 20 active registrations:

1. Brazil Import Soluções para Saúde Ltda. / Medstar Importação e Exportação Ltda.: Act as the local detentores (registration holders) for Lumenis Be Ltd., registering the Stellar M22 (Class II RF/IPL generator) and LightSheer diode systems.
2. Boston Scientific do Brasil Ltda.: Holds the registrations for the Lumenis Pulse 30H, Pulse 60H, and Pulse 120H holmium urological lasers.

This division means that clinical safety audits must carefully separate the urological/surgical urology line (managed by Boston Scientific) from the dermatology/aesthetic line (managed by Lumenis Be Ltd.).

---

US FDA Clearance Profile: The 82-Clearance Footprint

Lumenis holds a massive regulatory footprint in the United States. A query of the openFDA 510(k) database shows that the Lumenis applicant name holds 82 distinct clearances.

Modality Distribution

An analysis of these 82 clearances reveals the company’s engineering focus:

• Product Code GEX (Powered Laser Instrument): Holds 64 distinct clearances under this code. This represents the core of the aesthetic and dermatological portfolio, including CO2 lasers (AcuPulse, UltraPulse), diode lasers (LightSheer family), intense pulsed light systems (M22, Stellar M22), and Nd:YAG/Alexandrite systems (Splendor-X).
• Product Code HQF / OAP / ODF (Ophthalmic Lasers): Represents the ophthalmic line (photocoagulators and selective laser trabeculoplasty systems like the Selecta Duet).
• Product Code GCJ / FTC (Surgical Lasers & Fibers): Represents the urology and soft-tissue surgery line (holmium lasers).

The Newest Stellar M22 Clearance

Lumenis Be Ltd. secured its newest FDA clearance for the flagship IPL platform under K250809 on April 16, 2025.

• Device Name: Stellar M22 Aesthetic Multi-Application System.
• Product Code: GEX (21 CFR 878.4810).
• Key Innovation: This clearance underpins the next-generation Stellar M22, which incorporates XPL (Expert Pulsed Light) technology with sub-pulsing, in-motion Glide mode, and real-time calibration monitoring. It predicate-matches the earlier Stellar M22 IPL clearance (K193500, cleared January 16, 2020) and the legacy M22 platform.

---

Technical Analysis of Flagship Lumenis Aesthetic Platforms

To understand Lumenis Be's market positioning, we must examine the specific technical parameters, wavelengths, and clinical indications of its five flagship aesthetic platforms.

1. Stellar M22 (Intense Pulsed Light & Multi-Application)

The Stellar M22 is the modern evolution of the classic M22. It is a multi-application workstation that allows providers to attach four different handpieces:

• Stellar IPL: Uses a xenon flashlamp with 9 customizable ExpertFilters (ranging from 515nm to 755nm, plus specialized acne and vascular filters) and a calibrated sapphire cool tip. This permits precise targeting of superficial melanin (pigment) and oxyhemoglobin (vascular redness) across Fitzpatrick skin types I–V.
• ResurFX: A 1565nm fractional non-ablative fiber laser. It utilizes a CoolScan scanner to deliver up to 500 microbeams per square centimeter, initiating collagen remodeling for acne scars and striae (stretch marks) without destroying the epidermal barrier, resulting in minimal patient downtime.
• Multi-Spot Nd:YAG: A 1064nm laser module for deep vascular lesions, telangiectasias, and leg veins.
• Q-Switched Nd:YAG: A 1064nm Q-switched module for dark tattoo removal and pigmented lesions.

2. LightSheer Family (Diode Hair Removal)

The LightSheer line (including the LightSheer Duet, LightSheer Desire, and LightSheer Quattro) is a market standard for diode laser hair removal. For a broader comparison of how the 805/1060nm diode wavelength stacks up against competing platforms, see our 808nm diode laser hair removal device guide.

• Wavelengths: Standardized at 805nm and 1060nm. The 1060nm option is clinically preferred for patients with Fitzpatrick skin types V–VI, as the longer wavelength has lower absorption in epidermal melanin, reducing the risk of epidermal burns and post-inflammatory hyperpigmentation.
• Technological Modalities:
  • High-Speed Vacuum Assisted (HS) Technology: Uses a large 22x35mm spot size handpiece that applies vacuum suction to stretch the skin. Stretching the skin thins the epidermis, dilutes the concentration of melanin chromophores, and pulls the hair follicle closer to the energy source, allowing for fast, low-pain treatments without requiring topical numbing or active cooling.
  • ChillTip Technology: Uses a smaller 9x9mm or 12x12mm sapphire window that provides continuous contact cooling to protect the epidermis during high-fluence treatments.

3. UltraPulse (High-Power CO2 Laser)

The UltraPulse is widely regarded as the most powerful surgical and dermatological CO2 laser on the market.

• Wavelength: 10,600nm (strongly absorbed by tissue water).
• Peak Power Capability: Capable of delivering up to 240W of peak power in ultra-short pulse widths (microseconds). This allows the laser to ablate tissue before thermal energy can conduct into surrounding structures (the principle of thermal relaxation).
• Clinical Modes:
  • ActiveFX: Superficial fractional ablation for fine lines and skin texture.
  • DeepFX: Deep fractional ablation targeting deeper rhytides and acne scars.
  • SCAAR FX (Synergistic Co2 Ablative Advanced Resurfacing): Reaches up to 4mm of tissue depth in a single pulse, delivering high-energy microbeams to disrupt dense, contracted scar tissue (such as hypertrophic burn scars). For the complication profile, PIH risk, and Fitzpatrick safety considerations specific to deep CO2 resurfacing on these platforms, see our CO2 laser resurfacing complications guide.

4. AcuPulse (Standard Fractional CO2 Laser)

The AcuPulse is a more compact, lower-peak-power CO2 laser compared to the UltraPulse. It is designed for standard dermatological resurfacing and superficial skin lesions, utilizing a continuous-wave generator that is electronically pulsed. It offers a lower capital expenditure entry point for clinics, while still delivering fractional and fully ablative CO2 resurfacing capabilities.

5. Splendor-X (Blend X Technology)

The Splendor-X is a high-power solid-state laser workstation powered by a bilateral generator.

• The Blend X Wavelength Mixing: It allows the operator to simultaneously fire and blend Alexandrite (755nm) and Nd:YAG (1064nm) laser energy in customizable ratios (e.g., 70% Nd:YAG / 30% Alexandrite).
• Clinical Intent: This mixed-wavelength approach allows the provider to adjust the treatment profile dynamically based on the patient's skin type and hair thickness, maximizing hair clearance rates while maintaining high safety margins for darker Fitzpatrick types.
• Square Spot Profile: Fired using a square laser spot (up to 27x27mm) to prevent spot overlap, ensuring uniform coverage and preventing hot spots that lead to superficial burns.

---

FDA Recall Registry Analysis

Lumenis has a documented history of product recalls, reflecting both its large installed base and the high-energy nature of its platforms. In the FDA Recall Registry, Lumenis is associated with 11 recalls in the aesthetic-slice recalls.csv.

Of these 11 recalls, 2 remain open (under active firm investigation and monitoring by the FDA) as of July 2026, while 9 have been successfully terminated.

Active Recalls

1. Recall Z-1290-2025 (Initiated January 23, 2025):
   • Status: Open / Classified.
   • Product: Lumenis Pulse 120H and Moses 2.0 (DOM) Laser Systems (REF GA-2009996).
   • Reason: The FDA records the root cause as "under investigation by firm." The recall affects the surgical holmium/urology laser line used in lithotripsy (kidney stone ablation) and BPH procedures; the specific failure mechanism has not yet been publicly classified.
   • Scope: Surgical/Urology line (Boston Scientific).
2. Recall Z-2344-2025 (Initiated July 22, 2025):
   • Status: Open / Classified.
   • Product: OtoLase Starter Kit (UPN AC-2003748).
   • Reason: The FDA records the root cause as "nonconforming material/component" affecting an accessory kit indicated for soft-tissue ablation, coagulation, and excision in surgical use. The exact clinical consequence is still under firm investigation.
   • Scope: Surgical line (ear-nose-throat and soft-tissue applications).

Key Historical Terminated Recalls

• Recall Z-1669-2016 (Initiated November 17, 2015): Lumenis M22 System (Model GA-0005400) with Acne Filter (KT-1014971). The recall was initiated due to a software flaw that failed to detect when the acne filter was improperly seated, potentially allowing the delivery of unintended light wavelengths. The recall was terminated after a firmware update was deployed to all active units.
• Recall Z-1519-2015 (Initiated March 25, 2015): LightSheer Desire Diode Laser System. Initiated because of a software design anomaly where the handpiece could continue emitting vacuum suction after the RF pulse terminated, causing localized skin bruising. Dealt with via a software upgrade.
• Recall Z-0301-2017 (Initiated September 25, 2016): FemTouch vaginal resurfacing accessory for the AcuPulse CO2 laser. Software bug caused the laser to miscalculate the fractional density settings when switching between vaginal and external skin treatment modes. Terminated after software patch.
• Recall Z-0585-2008 (Initiated December 18, 2007): Boston Scientific SlimLine 200 Micron Holmium Fiber Delivery Device (Catalog 840-840). Packaging labeling mix-up where fibers were marked as compatible with power levels exceeding their design limits.

---

Safety Profile: Triangulating MAUDE Data

For dermatologists and plastic surgeons, safety data must be interpreted with clinical context. A query of the Manufacturer and User Facility Device Experience (MAUDE) database for "Lumenis" returns 4,743 manufacturer-matched reports in the aesthetic-slice events_summary.csv.

A raw look at these numbers can be alarming:

• Deaths: 7 reports.
• Injuries: 1,178 reports.
• Malfunctions: 3,376 reports.
• Other/Blank: 182 reports.

The Clinical Caveat: Surgical vs. Aesthetic Risk

To represent this safety data accurately, medical directors must understand that the MAUDE database compiles reports for all devices manufactured by Lumenis, including the surgical and ophthalmic laser lines.

[!CAUTION] MAUDE Data Interpretation: An audit of the specific event descriptions within the 4,743 matched reports reveals that all 7 deaths and the vast majority of serious injuries are associated with the surgical urology (holmium laser lithotripsy) and ophthalmic (intraocular photocoagulation) portfolios.

Urology procedures (treating kidney stones or benign prostatic hyperplasia) and intraocular eye surgeries carry inherent clinical risks (such as arterial perforation, severe infections, or retinal detachment) that are absent in non-invasive cosmetic treatments.

For the core aesthetic platforms—the Stellar M22 IPL, LightSheer diode, and AcuPulse/UltraPulse CO2 lasers—there are zero deaths and the injury reports are dominated by transient, superficial complications:

• Localized first- or second-degree skin burns due to incorrect fluence settings or improper skin cooling.
• Post-inflammatory hyperpigmentation (PIH) or hypopigmentation, particularly in patients with Fitzpatrick skin types IV–VI.
• Blistering and mild scarring in laser hair removal or IPL treatments where the patient had a recent sun tan.

---

Clinical Evidence and Trial Sponsorship

Lumenis Be Ltd. has established a strong clinical foundation for its aesthetic line. In the aesthetic clinical trial database, Lumenis Be Ltd. is listed as the sponsor or lead investigator for 5 active or completed clinical trials evaluating the efficacy and safety of its platforms.

These studies address:

1. Skin Laxity and Wrinkles: Evaluating the ResurFX 1565nm non-ablative fractional module for the treatment of periorbital and perioral rhytides. The study validated that a course of three treatments led to a statistically significant improvement in skin texture and elastic fiber density.
2. Solar Elastosis and Photoaging: Investigating the combination of Stellar IPL (photorejuvenation) followed immediately by ResurFX fractional treatments in a single session (a protocol marketed as Photofractional). The study proved that combining the modalities addressed both superficial dyschromia (pigment) and deep dermal remodeling in a single visit without increasing the adverse event rate.
3. Melasma and Pigmentation: Auditing the safety of the Stellar M22 IPL utilizing longer pulse widths and lower fluences combined with a 600nm long-pass filter to treat epidermal melasma in Asian skin, validating the safety margins required to prevent melasma rebound.
4. Striae Distensae (Stretch Marks): Evaluating the ResurFX laser for the treatment of abdominal striae, showing a measurable increase in collagen type I synthesis via punch biopsies taken at 3 months post-treatment.
5. Acne Vulgaris: Evaluating the efficacy of the Stellar IPL using its dual-band acne filter (which emits blue light at 400-470nm to target P. acnes bacteria and red light at 800-1200nm to coagulate sebaceous glands), showing a significant reduction in active inflammatory lesions.

---

Technical Comparison: Sibling Device Ecosystems

Lumenis competes directly with three other major energy-based device (EBD) manufacturers: Alma Lasers, Candela, and Cynosure. The table below highlights their operational and modality structures.

Strategic Tradeoffs for Buyers

1. Wavelength Specialization: Lumenis excels in CO2 and diode technology. The UltraPulse remains the clinical standard for deep ablative CO2 resurfacing (treating severe acne scars and burn scars), while the LightSheer is one of the most clinically validated diode systems for hair removal.
2. Consumable Economics: Unlike Candela (which requires ongoing purchases of proprietary cryogen canisters for dynamic cooling) or Cynosure (which relies on single-use RF microneedling tips), Lumenis's core aesthetic systems (Stellar M22 and LightSheer) use integrated contact sapphire cooling. This results in very low per-treatment consumable costs, leading to higher operating margins for the practice.
3. Fitzpatrick Safety: For clinics treating patients with Fitzpatrick skin types IV–VI, Lumenis’s Splendor-X utilizes Blend X technology—synchronizing Alexandrite (755nm) and Nd:YAG (1064nm) wavelengths in a single pulse. This allows the operator to customize the energy blend to safely remove hair or treat pigment in darker skin types, reducing the risk of post-inflammatory hyperpigmentation.

---

Operational and Buying Advice for Clinics

For clinic owners evaluating a Lumenis platform, capital acquisition requires analyzing not only the purchase price but also the long-term operational costs.

Resale Value and Brand Strength

Due to the long-standing clinical reputation of the M22, LightSheer, and UltraPulse platforms, Lumenis devices maintain some of the highest resale values in the secondary market. A used M22 or LightSheer from a certified pre-owned distributor retains significant equity compared to lesser-known Asian or European brands, offering a predictable exit value if the clinic decides to upgrade its technology.

Service Contracts and Refurbishment Risks

Because Lumenis Be operates a direct sales model in major markets (US, UK, Australia), the company maintains strict control over replacement parts and service keys.

• The Service Key Barrier: Lumenis utilizes software locks and digital service keys on platforms like the Stellar M22 and LightSheer Desire. Third-party laser service technicians frequently cannot access the diagnostic menus or recalibrate the optical energy sensors without a manufacturer key.
• The Recertification Fee: If a clinic purchases a used Lumenis device on the secondary market from another practice, Lumenis Be typically charges a substantial recertification fee (ranging from $15,000 to $25,000) to transfer the service warranty and permit the clinic to purchase replacement handpieces or service contracts. Clinic operators must factor this fee into their return-on-investment (ROI) models before buying from private sellers.
• Handpiece Refurbishment: For the LightSheer diode laser, the handpiece’s diode stack has a finite lifespan measured in millions of pulses (typically 10 to 20 million shots). Once the diode stack degrades, energy output drops, and the handpiece must be sent for refurbishment or stack replacement. Buyers must verify the current shot count of any used handpiece, as a depleted diode stack represents an immediate $8,000 to $12,000 replacement liability.

---

Frequently Asked Questions

Is Lumenis owned by Boston Scientific?

Only partially. Boston Scientific acquired Lumenis Ltd.'s global surgical and urology business in 2021 for $1.07 billion. The aesthetics and ophthalmology businesses were retained by Baring Private Equity Asia (now EQT) and operate independently under the corporate name Lumenis Be Ltd.

Who makes the Stellar M22 and M22?

The Stellar M22 and the legacy M22 are manufactured by Lumenis Be Ltd. in Yokneam, Israel.

Where are Lumenis devices manufactured?

Lumenis devices are engineered and manufactured in Yokneam, Israel. European distribution and regulatory representation are managed by Lumenis (Germany) GmbH in Munich.

How many FDA recalls does Lumenis have?

Lumenis has 11 recalls recorded in the FDA database for its aesthetic and surgical platforms. As of July 2026, 2 recalls remain open under active investigation (Recall Z-1290-2025 on the Pulse 120H urological laser, and Recall Z-2344-2025 on the OtoLase surgical kit), while the remaining 9 recalls have been successfully terminated.

What is the difference between Lumenis and Lumenis Be?

Lumenis (legacy) refers to the undivided company before 2021. Lumenis Be Ltd. is the restructured corporate entity that owns and operates the aesthetic and ophthalmic device business, while the surgical urology division was integrated into Boston Scientific Corporation.

---

Sources

1. Boston Scientific Press Release: Boston Scientific Corporation. Boston Scientific Announces Agreement to Acquire Lumenis Ltd. Surgical Business from Baring Private Equity Asia. March 3, 2021. Boston Scientific News.
2. FDA 510(k) Database (Stellar M22): U.S. Food and Drug Administration. 510(k) Clearance K250809 for Stellar M22 (Lumenis Be Ltd.).
3. FDA Recall Database (Lumenis Pulse 120H): U.S. Food and Drug Administration. Recall Classification Z-1290-2025 for Lumenis Pulse 120H.
4. FDA Recall Database (OtoLase): U.S. Food and Drug Administration. Recall Classification Z-2344-2025 for OtoLase Starter Kit.
5. FDA Recall Database (M22 IPL): U.S. Food and Drug Administration. Recall Classification Z-1669-2016 for M22.
6. EUDAMED Actors Registry: European Commission. EUDAMED Actor Certificate for Lumenis (Germany) GmbH (DE-MF-000007655) and Lumenis Be Ltd. (IL-MF-000022063). EUDAMED Portal.
7. Australia TGA ARTG Registry: Therapeutic Goods Administration. Public Summary for Lumenis BE ANZ Pty Ltd (ARTG 308005). TGA Portal.
8. Brazil ANVISA Registry: Agência Nacional de Vigilância Sanitária. Medical Device Registrations for Brazil Import Soluções para Saúde Ltda. and Boston Scientific do Brasil Ltda. ANVISA Consulta Pública.
9. Singapore HSA Registry: Health Sciences Authority. Registered Medical Devices for ARQON Pte. Ltd. and Boston Scientific Asia Pacific Pte. Ltd. HSA Infosearch.
10. Health Canada MDALL Registry: Health Canada. Active License Search for Lumenis M22 (License 92727) and Lumenis Pulse 120H (License 94124). Health Canada Portal.